{"protocolSection": {"identificationModule": {"nctId": "NCT02449473", "orgStudyIdInfo": {"id": "D2210C00014"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Study to Evaluate Efficacy & Safety of Tralokinumab in Subjects With Asthma Inadequately Controlled on Corticosteroids", "officialTitle": "A Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, 12-Week, Ph 2 Study to Evaluate the Effect of Tralokinumab on Airway Inflammation in Adults With Asthma Inadequately Controlled on Inhaled Corticosteroid (MESOS)", "acronym": "MESOS"}, "statusModule": {"statusVerifiedDate": "2019-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-09-29", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2017-06-21", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-06-21", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-05-18", "studyFirstSubmitQcDate": "2015-05-18", "studyFirstPostDateStruct": {"date": "2015-05-20", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-05-23", "resultsFirstSubmitQcDate": "2019-01-07", "resultsFirstPostDateStruct": {"date": "2019-01-08", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-01-07", "lastUpdatePostDateStruct": {"date": "2019-01-08", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "A Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, 12-Week, Phase 2 Study to Evaluate the Effect of Tralokinumab on Airway Inflammation in Adults with Asthma Inadequately Controlled on Inhaled Corticosteroid.", "detailedDescription": "This is a multicentre, randomized, double-blind, parallel group, placebo-controlled, phase 2 study to designed evaluate the effect of a 300 mg dose of tralokinumab administered subcutaneously every 2 weeks on airway inflammation in adults with asthma inadequately controlled on inhaled corticosteroids (ICS) with or without other controllers. Approximately 80 subjects will be randomized. Subjects will receive tralokinumab, or placebo, administered via subcutaneous injection at the study site, over a 12 week treatment period."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "Reactive Airways", "Respiratory Tract Disease", "Obstructive Tract Disease", "Lung Diseases"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 79, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Tralokinumab Dose Regimen", "type": "EXPERIMENTAL", "description": "Tralokinumab Subcutaneous Injection", "interventionNames": ["Biological: Tralokinumab"]}, {"label": "Placebo Dose Regimen", "type": "PLACEBO_COMPARATOR", "description": "Placebo Subcutaneous Injection", "interventionNames": ["Other: Placebo"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Tralokinumab", "description": "Subcutaneous Injection", "armGroupLabels": ["Tralokinumab Dose Regimen"]}, {"type": "OTHER", "name": "Placebo", "description": "Subcutaneous Injection", "armGroupLabels": ["Placebo Dose Regimen"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline to Week 12, Expressed as a Ratio, in Number of Airway Submucosal Eosinophils", "description": "The number of airway submucosal eosinophils per millimetre squared (mm\\^2) was determined by microscopic evaluation of bronchoscopic biopsies. The ratio of post-randomisation value at Week 12 to baseline value was computed as (Week 12 value / baseline value). The change from baseline to Week 12 (ratio) in the number of airway submucosal eosinophils is presented as geometric mean \u00b1 standard deviation (SD) of log values.", "timeFrame": "Baseline (Week 0) and Week 12"}], "secondaryOutcomes": [{"measure": "Change From Baseline to Week 12, Expressed as a Ratio, in Number of Blood Eosinophils", "description": "The blood eosinophil count was obtained from the total and differential white blood cell counts. The ratio of post-randomisation value at Week 12 to baseline value was computed as (Week 12 value / baseline value). The change from baseline to Week 12 (ratio) in the number of blood eosinophils is presented as geometric mean \u00b1 SD of log values.", "timeFrame": "Baseline (Week 0) and Week 12"}, {"measure": "Change From Baseline to Week 12, Expressed as a Ratio, in Number of Differential Sputum Eosinophils", "description": "Sputum induction was performed to obtain satisfactory samples of sputum originating from the airways. The ratio of post-randomisation value at Week 12 to baseline value was computed as (Week 12 value / baseline value). The change from baseline to Week 12 (ratio) in the number of eosinophils in induced sputum is presented as geometric mean \u00b1 SD of log values.", "timeFrame": "Baseline (Week 0) and Week 12"}, {"measure": "Change From Baseline to Week 12, Expressed as a Ratio, in Blood Free Eosinophil Cationic Protein (ECP) Concentrations", "description": "ECP concentrations were determined to assess evidence of activation of eosinophils in blood. The ratio of post-randomisation value at Week 12 to baseline value was computed as (Week 12 value / baseline value). The change from baseline to Week 12 (ratio) in blood free ECP concentrations is presented as geometric mean \u00b1 SD of log values.", "timeFrame": "Baseline (Week 0) and Week 12"}, {"measure": "Change From Baseline to Week 12, Expressed as a Ratio, in Sputum Free ECP Concentrations", "description": "ECP concentrations were determined to assess evidence of activation of eosinophils in sputum. The ratio of post-randomisation value at Week 12 to baseline value was computed as (Week 12 value / baseline value). The change from baseline to Week 12 (ratio) in sputum free ECP concentrations is presented as geometric mean \u00b1 SD of log values.", "timeFrame": "Baseline (Week 0) and Week 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Age 18 to 75 years\n2. Documented physician-diagnosed asthma for at least 12 months prior to enrolment (v1)\n3. Documented treatment with an asthma controller regimen requiring treatment with ICS (minimum dose of \u2265 250 ug fluticasone propionate via dry powder inhaler equivalents total daily dose) alone or in combination \u2265 6 months and that has been taken at a stable dose for at least 1 month prior to enrolment (v1)\n4. Additional maintenance asthma controller medications must be given at a stable dose for at least 1 month prior to v1.\n5. At enrolment (v1) the subject must have a predicted normal value (PNV) for the pre-bronchodilator (BD) FEV1\\>50% and more than 1L.\n6. Post-BD reversibility in FEV1 of \u226512% and \u2265200 mL at enrolment (v1).\n\nExclusion Criteria:\n\n1. History of interstitial lung disease, chronic obstructive pulmonary disease (COPD), or other clinically significant lung disease other than asthma.\n2. History of anaphylaxis following any biologic therapy.\n3. Hepatitis B, C or HIV\n4. Pregnant or breastfeeding\n5. History of cancer\n6. Current tobacco smoking or a history of tobacco smoking for \\>10 pack-years.\n7. Previous receipt of tralokinumab", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Christopher Brightling, MD", "affiliation": "Institute for Lung Health, United Kingdom", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Vancouver", "state": "British Columbia", "zip": "V5Z 1M9", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "Research Site", "city": "Montreal", "state": "Quebec", "zip": "H4A 3J1", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Research Site", "city": "Quebec", "zip": "G1V 4G5", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Research Site", "city": "Hvidovre", "zip": "2650", "country": "Denmark", "geoPoint": {"lat": 55.65719, "lon": 12.47364}}, {"facility": "Research Site", "city": "K\u00f8benhavn NV", "zip": "2400", "country": "Denmark", "geoPoint": {"lat": 55.67594, "lon": 12.56553}}, {"facility": "Research Site", "city": "Odense C", "zip": "5000", "country": "Denmark", "geoPoint": {"lat": 55.39594, "lon": 10.38831}}, {"facility": "Research Site", "city": "\u00c5lborg", "zip": "9000", "country": "Denmark"}, {"facility": "Research Site", "city": "\u00c5rhus C", "zip": "8000", "country": "Denmark", "geoPoint": {"lat": 56.15674, "lon": 10.21076}}, {"facility": "Research Site", "city": "Belfast", "zip": "BT12 6BA", "country": "United Kingdom", "geoPoint": {"lat": 54.59682, "lon": -5.92541}}, {"facility": "Research Site", "city": "Glasgow", "zip": "G12 OYN", "country": "United Kingdom", "geoPoint": {"lat": 55.86515, "lon": -4.25763}}, {"facility": "Research Site", "city": "Leicester", "zip": "LE3 9QP", "country": "United Kingdom", "geoPoint": {"lat": 52.6386, "lon": -1.13169}}, {"facility": "Research Site", "city": "London", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "Research Site", "city": "Manchester", "zip": "M23 9QZ", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "Research Site", "city": "Nottingham", "zip": "NG5 1PB", "country": "United Kingdom", "geoPoint": {"lat": 52.9536, "lon": -1.15047}}, {"facility": "Research Site", "city": "Southampton", "zip": "SO16 6YD", "country": "United Kingdom", "geoPoint": {"lat": 50.90395, "lon": -1.40428}}]}, "referencesModule": {"references": [{"pmid": "35537502", "type": "DERIVED", "citation": "Diver S, Sridhar S, Khalfaoui LC, Russell RJ, Emson C, Griffiths JM, de Los Reyes M, Yin D, Colice G, Brightling CE. Feno differentiates epithelial gene expression clusters: Exploratory analysis from the MESOS randomized controlled trial. J Allergy Clin Immunol. 2022 Oct;150(4):830-840. doi: 10.1016/j.jaci.2022.04.024. Epub 2022 May 7."}, {"pmid": "29793857", "type": "DERIVED", "citation": "Russell RJ, Chachi L, FitzGerald JM, Backer V, Olivenstein R, Titlestad IL, Ulrik CS, Harrison T, Singh D, Chaudhuri R, Leaker B, McGarvey L, Siddiqui S, Wang M, Braddock M, Nordenmark LH, Cohen D, Parikh H, Colice G, Brightling CE; MESOS study investigators. Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. Lancet Respir Med. 2018 Jul;6(7):499-510. doi: 10.1016/S2213-2600(18)30201-7. Epub 2018 May 21."}, {"pmid": "29536781", "type": "DERIVED", "citation": "Panettieri RA Jr, Wang M, Braddock M, Bowen K, Colice G. Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program. Immunotherapy. 2018 Mar 1;10(6):473-490. doi: 10.2217/imt-2017-0191. Epub 2018 Mar 14."}], "seeAlsoLinks": [{"label": "Related Info", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3064&filename=d2210c00014-sap-redacted2019.pdf"}, {"label": "Related Info", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3064&filename=d2210c00014-csp-Redacted2019.pdf"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "79 patients were randomised to receive investigational product (IP) and all those randomised received treatment.", "recruitmentDetails": "First patient enrolled: 29 Sep 2015; Last patient last visit: 21 Jun 2017. Study performed at 14 sites in 3 countries. Patients maintained on currently prescribed inhaled corticosteroid (\u2265250 micrograms fluticasone dry powder formulation equivalents total daily dose) + any additional maintenance asthma controller medication throughout the study.", "groups": [{"id": "FG000", "title": "Tralo 300 mg Q2W", "description": "Tralokinumab 300 milligrams (mg) administered subcutaneously every 2 weeks (Q2W) over a 12-week treatment period (up to 6 doses)."}, {"id": "FG001", "title": "Placebo", "description": "Placebo administered subcutaneously Q2W over a 12-week treatment period (up to 6 doses)."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "39"}, {"groupId": "FG001", "numSubjects": "40"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "39"}, {"groupId": "FG001", "numSubjects": "40"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All patients in the full analysis set (FAS) and who received any IP (tralokinumab or placebo) were included in the baseline analysis.", "groups": [{"id": "BG000", "title": "Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 12-week treatment period (up to 6 doses)."}, {"id": "BG001", "title": "Placebo", "description": "Placebo administered subcutaneously Q2W over a 12-week treatment period (up to 6 doses)."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "39"}, {"groupId": "BG001", "value": "40"}, {"groupId": "BG002", "value": "79"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "47.1", "spread": "14.2"}, {"groupId": "BG001", "value": "50.1", "spread": "14.2"}, {"groupId": "BG002", "value": "48.6", "spread": "14.2"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "43"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "36"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "3"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "34"}, {"groupId": "BG001", "value": "39"}, {"groupId": "BG002", "value": "73"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline to Week 12, Expressed as a Ratio, in Number of Airway Submucosal Eosinophils", "description": "The number of airway submucosal eosinophils per millimetre squared (mm\\^2) was determined by microscopic evaluation of bronchoscopic biopsies. The ratio of post-randomisation value at Week 12 to baseline value was computed as (Week 12 value / baseline value). The change from baseline to Week 12 (ratio) in the number of airway submucosal eosinophils is presented as geometric mean \u00b1 standard deviation (SD) of log values.", "populationDescription": "The FAS included all randomised patients who received any IP, irrespective of their protocol adherence and continued participation in the study. Only patients with data available at the timepoints of testing were included in the analyses.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Ratio", "timeFrame": "Baseline (Week 0) and Week 12", "groups": [{"id": "OG000", "title": "Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 12-week treatment period (up to 6 doses)."}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously Q2W over a 12-week treatment period (up to 6 doses)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "39"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.29", "spread": "2.06"}, {"groupId": "OG001", "value": "1.07", "spread": "1.87"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of change from baseline, expressed as a ratio, in airway submucosal eosinophils; Tralo 300 mg Q2W vs placebo. The null hypothesis was that the change in airway submucosal eosinophils at Week 12 on tralokinumab was equal to the corresponding change on placebo.", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "The model included treatment group as fixed effect and baseline log-transformed airway submucosal eosinophils as a continuous covariate. No interaction terms were included in the model. The analysis was performed using log-transformed data. All group comparisons from analysis of covariance (ANCOVA) model were based on Type III sums of squares.", "pValue": "0.3862", "statisticalMethod": "ANCOVA", "paramType": "Least square (LS) geometric mean ratio", "paramValue": "1.43", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.63", "ciUpperLimit": "3.27"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 12, Expressed as a Ratio, in Number of Blood Eosinophils", "description": "The blood eosinophil count was obtained from the total and differential white blood cell counts. The ratio of post-randomisation value at Week 12 to baseline value was computed as (Week 12 value / baseline value). The change from baseline to Week 12 (ratio) in the number of blood eosinophils is presented as geometric mean \u00b1 SD of log values.", "populationDescription": "The FAS included all randomised patients who received any IP, irrespective of their protocol adherence and continued participation in the study. Only patients with data available at the timepoints of testing were included in the analyses.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Ratio", "timeFrame": "Baseline (Week 0) and Week 12", "groups": [{"id": "OG000", "title": "Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 12-week treatment period (up to 6 doses)."}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously Q2W over a 12-week treatment period (up to 6 doses)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "37"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.10", "spread": "0.38"}, {"groupId": "OG001", "value": "0.91", "spread": "0.46"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of change from baseline, expressed as a ratio, in blood eosinophil count; Tralo 300 mg Q2W vs placebo.", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "The repeated measures analysis included treatment group, baseline log-transformed eosinophils and visit as fixed effects. Treatment-by-visit interaction was also included. The analysis was performed using log-transformed data. A restricted maximum likelihood (REML) approach was used. An unstructured variance-covariance matrix was used to model the within-subject errors.", "pValue": "0.0546", "statisticalMethod": "Repeated measures analysis", "paramType": "LS geometric mean ratio", "paramValue": "1.21", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.00", "ciUpperLimit": "1.48"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 12, Expressed as a Ratio, in Number of Differential Sputum Eosinophils", "description": "Sputum induction was performed to obtain satisfactory samples of sputum originating from the airways. The ratio of post-randomisation value at Week 12 to baseline value was computed as (Week 12 value / baseline value). The change from baseline to Week 12 (ratio) in the number of eosinophils in induced sputum is presented as geometric mean \u00b1 SD of log values.", "populationDescription": "The FAS included all randomised patients who received any IP, irrespective of their protocol adherence and continued participation in the study. Only patients with data available at the timepoints of testing were included in the analyses.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Ratio", "timeFrame": "Baseline (Week 0) and Week 12", "groups": [{"id": "OG000", "title": "Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 12-week treatment period (up to 6 doses)."}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously Q2W over a 12-week treatment period (up to 6 doses)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "17"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.20", "spread": "3.16"}, {"groupId": "OG001", "value": "0.47", "spread": "3.63"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of change from baseline, expressed as a ratio, in differential sputum eosinophils; Tralo 300 mg Q2W vs placebo.", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "The repeated measures analysis included treatment group, baseline log-transformed differential sputum eosinophils and visit as fixed effects. Treatment-by-visit interaction was also included. The analysis was performed using log-transformed data. A REML approach was used. An unstructured variance-covariance matrix was used to model the within-subject errors.", "pValue": "0.6334", "statisticalMethod": "Repeated measures analysis", "paramType": "LS geometric mean ratio", "paramValue": "0.57", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.06", "ciUpperLimit": "6.00"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 12, Expressed as a Ratio, in Blood Free Eosinophil Cationic Protein (ECP) Concentrations", "description": "ECP concentrations were determined to assess evidence of activation of eosinophils in blood. The ratio of post-randomisation value at Week 12 to baseline value was computed as (Week 12 value / baseline value). The change from baseline to Week 12 (ratio) in blood free ECP concentrations is presented as geometric mean \u00b1 SD of log values.", "populationDescription": "The FAS included all randomised patients who received any IP, irrespective of their protocol adherence and continued participation in the study. Only patients with data available at the timepoints of testing were included in the analyses.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Ratio", "timeFrame": "Baseline (Week 0) and Week 12", "groups": [{"id": "OG000", "title": "Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 12-week treatment period (up to 6 doses)."}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously Q2W over a 12-week treatment period (up to 6 doses)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.07", "spread": "0.40"}, {"groupId": "OG001", "value": "0.92", "spread": "0.47"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of change from baseline, expressed as a ratio, in blood free ECP concentration; Tralo 300 mg Q2W vs placebo.", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "The repeated measures analysis included treatment group, baseline log-transformed blood free ECP and visit as fixed effects. Treatment-by-visit interaction was also included. The analysis was performed using log-transformed data. A REML approach was used. An unstructured variance-covariance matrix was used to model the within-subject errors.", "pValue": "0.3769", "statisticalMethod": "Repeated measures analysis", "paramType": "LS geometric mean ratio", "paramValue": "1.11", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.88", "ciUpperLimit": "1.40"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 12, Expressed as a Ratio, in Sputum Free ECP Concentrations", "description": "ECP concentrations were determined to assess evidence of activation of eosinophils in sputum. The ratio of post-randomisation value at Week 12 to baseline value was computed as (Week 12 value / baseline value). The change from baseline to Week 12 (ratio) in sputum free ECP concentrations is presented as geometric mean \u00b1 SD of log values.", "populationDescription": "The FAS included all randomised patients who received any IP, irrespective of their protocol adherence and continued participation in the study. Only patients with data available at the timepoints of testing were included in the analyses.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Ratio", "timeFrame": "Baseline (Week 0) and Week 12", "groups": [{"id": "OG000", "title": "Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 12-week treatment period (up to 6 doses)."}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously Q2W over a 12-week treatment period (up to 6 doses)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "17"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.66", "spread": "1.21"}, {"groupId": "OG001", "value": "1.83", "spread": "1.41"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of change from baseline, expressed as a ratio, in sputum free ECP concentration; Tralo 300 mg Q2W vs placebo.", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "The repeated measures analysis included treatment group, baseline log-transformed sputum free ECP and visit as fixed effects. Treatment-by-visit interaction was also included. The analysis was performed using log-transformed data. A REML approach was used. An unstructured variance-covariance matrix was used to model the within-subject errors.", "pValue": "0.1126", "statisticalMethod": "Repeated measures analysis", "paramType": "LS geometric mean ratio", "paramValue": "0.49", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.20", "ciUpperLimit": "1.20"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "12 weeks", "description": "Data is reported for adverse events during the treatment period (onset date \u2265 the first day of IP and \u2264 the last day of IP + 2 weeks). Patient population was the safety analysis set which included all patients who received any IP, classified according to the treatment they actually received.", "eventGroups": [{"id": "EG000", "title": "Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 12-week treatment period (up to 6 doses).", "deathsNumAffected": 0, "deathsNumAtRisk": 39, "seriousNumAffected": 0, "seriousNumAtRisk": 39, "otherNumAffected": 30, "otherNumAtRisk": 39}, {"id": "EG001", "title": "Placebo", "description": "Placebo administered subcutaneously Q2W over a 12-week treatment period (up to 6 doses).", "deathsNumAffected": 0, "deathsNumAtRisk": 40, "seriousNumAffected": 1, "seriousNumAtRisk": 40, "otherNumAffected": 27, "otherNumAtRisk": 40}], "seriousEvents": [{"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 40}]}], "otherEvents": [{"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 8, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 20, "numAffected": 17, "numAtRisk": 40}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 18, "numAffected": 9, "numAtRisk": 40}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 40}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 40}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}]}, {"term": "Injection site erythema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}]}, {"term": "Injection site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}]}, {"term": "Injection site pruritus", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}]}, {"term": "Injection site swelling", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 40}]}, {"term": "Weight increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 40}]}, {"term": "Procedural pain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 40}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 6, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 40}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 40}]}, {"term": "Rhinorrhoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 40}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "The results for differential sputum eosinophils and sputum free ECP levels should be viewed cautiously due to the small sample size and wide variability in results for sputum analyses."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "LTE60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Global Clinical Lead", "organization": "AstraZeneca", "email": "ClinicalTrialTransparency@astrazeneca.com", "phone": "+1 301-398-0582"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2016-01-15", "uploadDate": "2019-01-07T02:26", "filename": "Prot_000.pdf", "size": 1634086}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2017-07-28", "uploadDate": "2019-01-07T02:28", "filename": "SAP_001.pdf", "size": 1488773}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M10293", "name": "Inflammation", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}}, "hasResults": true}